A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Recruiting

Phase 3

KarXT & KarX-ECA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Sponsor:

Bristol-Myers Squibb

Code:

NCT06976216

Conditions

Alzheimer's Disease

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Not accepted

Interventions

KarXT

KarX-EC

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-23. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-05-28.